Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415504 | 0.76 | CA2 (0.41) | TP53CA2CA1CA12CA7 | |
| SCHEMBL28229721 | 0.76 | FAAH (0.39) | TP53LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL27675605 | 0.76 | TP53 (0.43) | TP53LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL5888772 | 0.75 | TP53 (0.37) | TP53SMN1; SMN2MAPK1DNM1ALDH1A1 | |
| SCHEMBL27289489 | 0.75 | TP53 (0.37) | TP53SMN1; SMN2MAPK1DNM1TSHR | |
| SCHEMBL6113068 | 0.73 | TP53 (0.45) | TP53SMN1; SMN2MAPK1DNM1TSHR | |
| SCHEMBL28313790 | 0.73 | CA2 (0.36) | TP53LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL7103231 | 0.73 | TP53 (0.32) | TP53LCKPPARDZDHHC20ZDHHC2 | |
| SCHEMBL3263489 | 0.71 | TP53 (0.34) | TP53SMN1; SMN2MAPK1DNM1ALDH1A1 | |
| SCHEMBL14892962 | 0.71 | TP53 (0.43) | TP53DNM1FDPSCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2295427-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295426-A1 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7838524-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | TP53 3/4885LCK 2019/4885PPARD 1341/4885 |
| US-20110136809-A1 | Substituted Pyrazolyl Urea Derivatives Useful In The Treatment Of Cancer | UMPS, SLC14A1, TP53 | TP53 3/4885LCK 2019/4885PPARD 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.